See Supplemental Patient Information
- Life threatening paradoxical bronchospasm may occur. Discontinue use immediately and institute alternative therapy if paradoxical bronchospasm occurs
- Deterioration of asthma may occur. Need for increased dosage/frequency of levoalbuterol indicates destabilization of asthma and may require re-evaluation of the patient and treatment regimen
- Consider adding anti-inflammatory agents, e.g. corticosteroids, to the therapeutic regimen, as use of a beta-adrenergic agonist alone may not be adequate to control asthma, in many patients
- Levoalbuterol can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure, ECG changes and/or symptoms. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
- Do not exceed recommended doses. Excessive use can cause fatalities in patients with asthma
- Immediate hypersensitivity reactions manifested as urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema can occur after administration of racemic albuterol
Cautions: Use cautiously in
- Renal impairment
- Hypertension
- CAD
- Cardiac arrhythmias
- Diabetes mellitus
- Hyperthyroidism
- Convulsive disorder
- Hypokalemia
- Patients responsive to sympathomimetic amines
Supplemental Patient Information
- Advise patients not to use levalbuterol inhaler more frequently than recommended
- Advise patient to consult their physician, if inhalation aerosol becomes less effective for symptomatic relief, or symptoms become worse, or if they need to use the product more frequently than usual
Pregnancy Category:C
Breastfeeding: No published data exists on the use of oral or inhaled levalbuterol during lactation. However, inhaled bronchodilators are considered acceptable for use during breastfeeding, due to low bioavailability and maternal serum levels after use. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 26 May 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Xopenex HFA 45 MCG/ACT AERO [Inhaler] (SUNOVION PHARMACEUTICALS)
15 act = $59.99
45 act = $155.97 - Xopenex 1.25 MG/3ML NEBU [Box] (SUNOVION PHARMACEUTICALS)
72 3ml = $160.99
216 3ml = $459.96 - Xopenex 0.63 MG/3ML NEBU [Box] (SUNOVION PHARMACEUTICALS)
72 3ml = $157
216 3ml = $451.99 - Xopenex 0.31 MG/3ML NEBU [Box] (SUNOVION PHARMACEUTICALS)
72 3ml = $139.98
216 3ml = $399.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.